|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C,
Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY, Weller M, Lee EQ, Alexander BM,
Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM,
Chiocca EA, et al: Glioblastoma in adults: A society for
neuro-oncology (SNO) and european society of neuro-oncology (EANO)
consensus review on current management and future directions. Neuro
Oncol. 22:1073–1113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller KD, Ostrom QT, Kruchko C, Patil N,
Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL and
Barnholtz-Sloan JS: Brain and other central nervous system tumor
statistics, 2021. CA Cancer J Clin. 71:381–406. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heffron TP: Challenges of developing
small-molecule kinase inhibitors for brain tumors and the need for
emphasis on free drug levels. Neuro Oncol. 20:307–312. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Le Rhun E, Preusser M, Roth P, Reardon DA,
van den Bent M, Wen P, Reifenberger G and Weller M: Molecular
targeted therapy of glioblastoma. Cancer Treat Rev. 80:1018962019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perryman R, Renziehausen A, Shaye H,
Kostagianni AD, Tsiailanis AD, Thorne T, Chatziathanasiadou MV,
Sivolapenko GB, El Mubarak MA, Han GW, et al: Inhibition of the
angiotensin II type 2 receptor AT2R is a novel
therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA.
119:e21162891192022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao TQ, Wainwright DA, Lee-Chang C, Miska
J, Sonabend AM, Heimberger AB and Lukas RV: Next steps for
immunotherapy in glioblastoma. Cancers (Basel). 14:40232022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Todo T, Ito H, Ino Y, Ohtsu H, Ota Y,
Shibahara J and Tanaka M: Intratumoral oncolytic herpes virus G47∆
for residual or recurrent glioblastoma: A phase 2 trial. Nat Med.
28:1630–1639. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anselmo P, Maranzano E, Selimi A,
Lupattelli M, Palumbo I, Bini V, Casale M, Trippa F, Bufi A,
Arcidiacono F and Aristei C: Clinical characterization of
glioblastoma patients living longer than 2 years: A retrospective
analysis of two Italian institutions. Asia Pac J Clin Oncol.
17:273–279. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang H, Yu K, Li M, Cui Y, Ren X, Yang C,
Zhao X and Lin S: Classification of progression patterns in
glioblastoma: Analysis of predictive factors and clinical
implications. Front Oncol. 10:5906482020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pasqualetti F, Montemurro N, Desideri I,
Loi M, Giannini N, Gadducci G, Malfatti G, Cantarella M, Gonnelli
A, Montrone S, et al: Impact of recurrence pattern in patients
undergoing a second surgery for recurrent glioblastoma. Acta Neurol
Belg. 122:441–446. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jovčevska I: Genetic secrets of long-term
glioblastoma survivors. Bosn J Basic Med Sci. 19:116–124.
2019.PubMed/NCBI
|
|
15
|
Gately L, McLachlan SA, Philip J, Rathi V
and Dowling A: Molecular profile of long-term survivors of
glioblastoma: A scoping review of the literature. J Clin Neurosci.
68:1–8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lei CG, Jia XY and Sun WJ: Establish
six-gene prognostic model for glioblastoma based on multi-omics
data of TCGA database. Yi Chuan. 43:665–679. 2021.PubMed/NCBI
|
|
17
|
Richardson TE, Kumar A, Xing C, Hatanpaa
KJ and Walker JM: Overcoming the odds: Toward a molecular profile
of long-term survival in glioblastoma. J Neuropathol Exp Neurol.
79:1031–1037. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Butler M, Pongor L, Su YT, Xi L, Raffeld
M, Quezado M, Trepel J, Aldape K, Pommier Y and Wu J: MGMT status
as a clinical biomarker in glioblastoma. Trends Cancer. 6:380–391.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Henriksen M, Johnsen KB, Andersen HH,
Pilgaard L and Duroux M: MicroRNA expression signatures determine
prognosis and survival in glioblastoma multiforme-a systematic
overview. Mol Neurobiol. 50:896–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Zhang J, Yan W, You G, Bao Z, Li
S, Kang C, Jiang C, You Y, Zhang Y, et al: Whole-genome microRNA
expression profiling identifies a 5-microRNA signature as a
prognostic biomarker in Chinese patients with primary glioblastoma
multiforme. Cancer. 119:814–824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Srinivasan S, Patric IRP and Somasundaram
K: A ten-microRNA expression signature predicts survival in
glioblastoma. PLoS One. 6:e174382011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niyazi M, Zehentmayr F, Niemöller OM,
Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, Tonn JC, Atkinson M,
Mörtl S and Belka C: MiRNA expression patterns predict survival in
glioblastoma. Radiat Oncol. 6:1532011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Areeb Z, Stylli SS, Koldej R, Ritchie DS,
Siegal T, Morokoff AP, Kaye AH and Luwor RB: MicroRNA as potential
biomarkers in Glioblastoma. J Neurooncol. 125:237–248. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rolle K: miRNA Multiplayers in glioma.
From bench to bedside. Acta Biochim Pol. 62:353–365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen L and Kang C: miRNA interventions
serve as ‘magic bullets’ in the reversal of glioblastoma hallmarks.
Oncotarget. 6:38628–38642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ananta JS, Paulmurugan R and Massoud TF:
Tailored nanoparticle codelivery of antimiR-21 and antimiR-10b
augments Glioblastoma Cell Kill by Temozolomide: Toward a
‘personalized’ anti-microRNA therapy. Mol Pharm. 13:3164–3175.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lopez-Bertoni H, Kozielski KL, Rui Y, Lal
B, Vaughan H, Wilson DR, Mihelson N, Eberhart CG, Laterra J and
Green JJ: Bioreducible polymeric nanoparticles containing
multiplexed cancer stem cell regulating miRNAs inhibit Glioblastoma
growth and prolong survival. Nano Lett. 18:4086–4094. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gu JJ, Zhang JH, Chen HJ and Wang SS:
MicroRNA-130b promotes cell proliferation and invasion by
inhibiting peroxisome proliferator-activated receptor-γ in human
glioma cells. Int J Mol Med. 37:1587–1593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu JJ, Fan KC, Zhang JH, Chen HJ and Wang
SS: Suppression of microRNA-130b inhibits glioma cell proliferation
and invasion, and induces apoptosis by PTEN/AKT signaling. Int J
Mol Med. 41:284–292. 2018.PubMed/NCBI
|
|
32
|
Zhu G, Wang Y, Mijiti M, Wang Z, Wu PF and
Jiafu D: Upregulation of miR-130b enhances stem cell-like phenotype
in glioblastoma by inactivating the Hippo signaling pathway.
Biochem Biophys Res Commun. 465:194–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Malzkorn B, Wolter M, Liesenberg F,
Grzendowski M, Stühler K, Meyer HE and Reifenberger G:
Identification and functional characterization of microRNAs
involved in the malignant progression of gliomas. Brain Pathol.
20:539–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katakowski M, Zheng X, Jiang F, Rogers T,
Szalad A and Chopp M: MiR-146b-5p suppresses EGFR expression and
reduces in vitro migration and invasion of glioma. Cancer Invest.
28:1024–1030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pandita A, Aldape KD, Zadeh G, Guha A and
James CD: Contrasting in vivo and in vitro fates of glioblastoma
cell subpopulations with amplified EGFR. Genes Chromosomes Cancer.
39:29–36. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
William D, Mokri P, Lamp N, Linnebacher M,
Classen CF, Erbersdobler A and Schneider B: Amplification of the
EGFR gene can be maintained and modulated by variation of EGF
concentrations in in vitro models of glioblastoma multiforme. PLoS
One. 12:e01852082017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S,
Wang Q, Yan Y, Kang C, Jin S, et al: miR-146b-5p inhibits glioma
migration and invasion by targeting MMP16. Cancer Lett.
339:260–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Le Zhang, Wang J, Fu Z, Ai Y, Li Y and
Wang Y and Wang Y: Sevoflurane suppresses migration and invasion of
glioma cells by regulating miR-146b-5p and MMP16. Artif Cells
Nanomed Biotechnol. 47:3306–3314. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stetler-Stevenson WG, Aznavoorian S and
Liotta LA: Tumor cell interactions with the extracellular matrix
during invasion and metastasis. Annu Rev Cell Biol. 9:541–573.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu J, Xu J, Li H, Sun C, Yu L, Li Y, Shi
C, Zhou X, Bian X, Ping Y, et al: miR-146b-5p functions as a tumor
suppressor by targeting TRAF6 and predicts the prognosis of human
gliomas. Oncotarget. 6:29129–29142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qian Z, Zhou S, Zhou Z, Yang X, Que S, Lan
J, Qiu Y and Lin Y: miR-146b-5p suppresses glioblastoma cell
resistance to temozolomide through targeting TRAF6. Oncol Rep.
38:2941–2950. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun J, Zhao B, Du K and Liu P: TRAF6
correlated to invasion and poor prognosis of glioblastoma via
elevating MMP9 expression. Neuroreport. 30:127–133. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang H, Tan L, Dong X, Liu L, Jiang Q, Li
H, Shi J, Yang X, Dai X, Qian Z and Dong J: MiR-146b-5p suppresses
the malignancy of GSC/MSC fusion cells by targeting SMARCA5. Aging.
12:13647–13667. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang W, Yu H, Shen Y, Liu Y, Yang Z and
Sun T: MiR-146b-5p overexpression attenuates stemness and
radioresistance of glioma stem cells by targeting
HuR/lincRNA-p21/β-catenin pathway. Oncotarget. 7:41505–41526. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Khwaja SS, Cai C, Badiyan SN, Wang X and
Huang J: The immune-related microRNA miR-146b is upregulated in
glioblastoma recurrence. Oncotarget. 9:29036–29046. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li Y, Li W, Zeng X, Tang X, Zhang S, Zhong
F, Peng X, Zhong Y, Rosol TJ, Deng X, et al: The role of
microRNA-148a and downstream DLGAP1 on the molecular regulation and
tumor progression on human glioblastoma. Oncogene. 38:7234–7248.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang H, Pan JQ, Luo L, Ning XJ, Ye ZP, Yu
Z and Li WS: NF-κB induces miR-148a to sustain TGF-β/Smad signaling
activation in glioblastoma. Mol Cancer. 14:22015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wong HA, Fatimy RE, Onodera C, Wei Z, Yi
M, Mohan A, Gowrisankaran S, Karmali P, Marcusson E, Wakimoto H, et
al: The cancer genome atlas analysis predicts microRNA for
targeting cancer growth and vascularization in Glioblastoma. Mol
Ther. 23:1234–1247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu TJ, Qiu P, Zhang YB, Yu SY, Xu GM and
Yang W: MiR-148a inhibits the proliferation and migration of
glioblastoma by targeting ITGA9. Hum Cell. 32:548–556. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guichet P-O, Guelfi S, Teigell M, Hoppe L,
Bakalara N, Bauchet L, Duffau H, Lamszus K, Rothhut B and Hugnot
JP: Notch1 stimulation induces a vascularization switch with
pericyte-like cell differentiation of glioblastoma stem cells. Stem
Cells. 33:21–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cui D, Sajan P, Shi J, Shen Y, Wang K,
Deng X, Zhou L, Hu P and Gao L: MiR-148a increases glioma cell
migration and invasion by downregulating GADD45A in human gliomas
with IDH1 R132H mutations. Oncotarget. 8:25345–25361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim J, Zhang Y, Skalski M, Hayes J, Kefas
B, Schiff D, Purow B, Parsons S, Lawler S and Abounader R:
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to
regulate EGFR and apoptosis in glioblastoma. Cancer Res.
74:1541–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cai Q, Zhu A and Gong L: Exosomes of
glioma cells deliver miR-148a to promote proliferation and
metastasis of glioblastoma via targeting CADM1. Bull Cancer.
105:643–651. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fang Z, Weng Y, Xiao F and Yu J: LncRNA
RP11-390F4.3 inhibits invasion and migration of glioblastoma cells
by downregulating ROCK1. Neuroreport. 32:888–893. 2021. View Article : Google Scholar : PubMed/NCBI
|
